Opinion
Video
Paper aims to explore questions surrounding cytoreductive nephrectomy
Author(s):
"Despite the results of SURTIME and CARMENA, among others, we continue to hear discussions about the role of cytoreductive nephrectomy in conferences and literature, suggesting that this remains a question that has not been fully addressed," says Jaleh Fallah, MD.
In this video, Jaleh Fallah, MD, discusses the motivation behind the Journal of the National Cancer Institute paper, “Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis.” Fallah is a medical oncologist with the FDA.
Transcription:
Why did the FDA decide this project was worth conducting?
The Oncology Center of Excellence or OCE supports FDA oncology staff who participate in regulatory science research, including internal research projects and collaborations with external experts. Scientific research that can inform our regulatory work is part of our mission. Despite the results of SURTIME and CARMENA, among others, we continue to hear discussions about the role of cytoreductive nephrectomy in conferences and literature, suggesting that this remains a question that has not been fully addressed, particularly given the changes in the therapeutic landscape since those trials were conducted, and we didn't have access to the data needed to explore the study question.
This transcription was edited for clarity.
